论文部分内容阅读
目的分析该院Ⅱ型糖尿病患者使用口服降糖药物的详情。方法选择该院2013年-2014年药库中口服降糖药数据为研究资料,使用DDD分析和金额排序法,对相关资料进行详细分析。结果 2013-2014年DDDS排名前三的药物为二甲双胍,格列吡嗪和瑞格列奈。与2013年相比,阿卡波糖的DDDS呈现出明显上升趋势,格列齐特呈现出下降趋势。结论二甲双胍,磺酰脲类药物和糖苷酶抑制剂治疗Ⅱ型糖尿病的临床效果较好,副作用少,因此使用频率较高,发展空间较大。
Objective To analyze the use of oral antidiabetic drugs in patients with type 2 diabetes in our hospital. Methods The data of oral hypoglycemic agents in the pharmacy of the hospital from 2013 to 2014 were selected as the research data, and the related data were analyzed in detail by using DDD analysis and the amount ranking method. Results The top three DDDS drugs in 2013-2014 were metformin, glipizide and repaglinide. Compared with 2013, DDDS of acarbose showed a clear upward trend, and the trend of gliclazide showed a downward trend. Conclusions Metformin, sulfonylureas and glycosidase inhibitors have a good clinical effect and less side effects in the treatment of type Ⅱ diabetes mellitus. Therefore, the use of metformin, sulfonylureas and glycosidase inhibitors has a higher frequency of use and greater development potential.